Table 3.

Prices of 15 innovative anti-cancer medicines before and after policy implementation (CNY).

No.	Name	Before	After	Rate of change/%
1	Rituximab	4,346.25	2,802.47	−35.52
2	Trastuzumab	999.97	345.45	−65.45
3	Bevacizumab	1,300.00	499.50	−61.58
4	Sorafenib	1,666.67	812.00	−51.28
5	Bortezomib	1,443.43	698.97	−51.58
6	Erlotinib	460.00	195.00	−57.61
7	Nimotuzumab	972.40	486.20	−50.00
8	Apatinib	731.34	462.40	−36.77
9	Chidamide	—	669.90	—
10	Fulvestrant	181.24	79.68	−56.04
11	Everolimus	495.00	296.00	−40.20
12	Lenalidomide	2,104.46	826.49	−60.73
13	Lapatinib	—	245.00	—
14	Abiraterone	—	579.68	—
15	Recombinant human endostatin	544.16	357.00	−34.39

“—” means that this drug could not be available in this time period.